Biotage AB appointment of new CEO

15-Aug-2024 - BiotageAB announced the appointment of Frederic Vanderhaegen as Chief Executive Officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member. Frederic Vanderhaegenisaprominentlife ...

Biotage CEO & President steps down from his role

08-Jan-2024 - While the business of Biotage continues to perform well, following consultation with the Board Tomas Blomquist will leave his role as CEO & President of Biotage AB with immediate effect. The Chairman of the Board, Torben Jørgensen, has been appointed by the Board of Directors as interim CEO while ...

Biotage acquires ATDBio

Biotage strengthens its position in DNA and RNA Oligonucleotide synthesis and purification

22-Oct-2021 - Biotage AB has entered into an agreement to acquire all outstanding shares in the privately held company ATDBio Limited based in Oxford and Southampton, UK, for a total purchase price of approx. 45 MGBP on a debt free and cash free basis (corresponding to approx. 534.4 MSEK) financed through a ...

Biotage Receives the SwedenBIO Award 2019

06-Dec-2019 - For the 13th time, the SwedenBIO Award was awarded on Wednesday night. This year’s winner is Biotage AB. Biotage is praised for contributing to the Swedish life science community for over three decades with dedication and endurance. Biotage has grown into an international company, with successful ...

Strategic Collaboration between Biotage and Yingsheng on the Chinese Market for Clinical Mass Spectrometry Applications

04-Jun-2019 - Biotage AB announced its strategic collaboration with Shandong Yingsheng Biotechnology Co., Ltd.. Yingsheng is mainly focused on independently researching, producing and selling in vitro diagnostic reagents and medical equipment, building a genetic detection platform and mass spectrometry ...

Tomas Blomquist: New CEO & President of Biotage

28-May-2019 - Biotage has appointed Tomas Blomquist as the new CEO and President of Biotage AB. Tomas Blomquist, most recently Vice President EMEA Cardimetabolic at Abbott, will start his assignment on November 6, 2019, and will then take over the responsibility for the Biotage group and its + 400 employees. ...

Biotage acquires PhyNexus

Strengthening position in lab-scale purification of biomolecules

04-Dec-2018 - Biotage AB has entered into an agreement to acquire all outstanding shares in the privately held company PhyNexus, Inc. (PhyNexus) based in California, US, for a total purchase price of approx. USD 21.5 million financed through a combination of newly issued shares in Biotage and existing cash at ...

Biotage acquires Horizon Technology

Strengthens position in environmental and food safety

08-Dec-2017 - Biotage AB has entered into an agreement to acquire all outstanding shares in the privately held company Horizon Technology, Inc. (Horizon) based in New Hampshire, US, at a purchase price of approx. USD 18.4 million, corresponding to approx. SEK 153 million, based on an enterprise value of ...

Biotage Announces Peptide Research Collaboration with the Laboratory of Peptide and Protein Chemistry and Biology in Florence, Italy

06-Jun-2011 - Biotage announced a collaborative research agreement with The Laboratory of Peptide & Protein Chemistry & Biology (PeptLab) located in Florence, Italy. The peptide research facility, led by Professor Anna Maria Papini, has agreed to contribute technical input towards the future development of ...

Biotage Announces Research Collaboration with University of Copenhagen for Peptide Synthesis

18-May-2010 - Biotage announced an agreement to extend the research collaboration with Professor Knud J. Jensen at the Faculty of Life Sciences, University of Copenhagen, to develop new applications on the Biotage Syro Wave in the field of synthetic peptide and protein chemistry. The collaboration builds on ...